Scottsdale, Ariz.-based East Valley Urology has completed the first three prostate cancer procedures in PROCEPT BioRobotics’ FDA-approved WATER IV trial using Aquablation therapy. The outpatient procedures, performed by Rahul Mehan, MD, were completed without complications and with same-day discharge, according to a July 23 press release.
The trial compares Aquablation therapy — a robotically controlled waterjet procedure — to radical prostatectomy in men with localized prostate cancer (grade group 1 to 3). The milestone demonstrates the potential for treating prostate cancer in a more scalable, cost-effective outpatient setting, according to the release.
Aquablation aims to offer a middle-ground approach by removing most of the prostate and diagnosed cancer while potentially preserving function. The trial results are pending.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.